Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

Surfaxin Phase 2 BPD Clinical Data Selected and Presented as Platform Presentation

Aerosurf Utilizing Chrysalis Aerosol-Generator Technology Demonstrates Optimal Functional Activity

WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that results from its previously completed Phase 2 clinical trial of Surfaxin(r) (lucinactant intratracheal suspension) for the prevention and treatment of Bronchopulmonary Dysplasia (BPD) were selected and presented as a platform presentation at the Pediatric Academic Societies' (PAS) Annual Meeting in Toronto, Canada. Also presented at PAS were data regarding Discovery's novel aerosolized KL-4 surfactant, Aerosurf(tm) (lucinactant for inhalation). The Pediatric Academic Societies' annual meeting is internationally recognized as the largest, most relevant medical meeting dedicated to pediatric critical care research. These data were presented for the first time to the medical community.

Phase 2 Clinical Trial of Surfaxin(r) for the Prevention and Treatment of BPD

Carl Bose, MD, Director of Neonatology and Professor of Pediatrics at University of North Carolina and Chairman of the Discovery BPD Clinical Study Steering Committee, presented an overview of key trial data. These data suggest that Surfaxin, when administered beyond the standard acute Respiratory Distress Syndrome (RDS) treatment period, may represent a novel therapeutic option for infants at risk for developing BPD. BPD is a chronic, debilitating lung disease affecting premature infants who survive treatment for RDS. Presently, there are no approved pharmaceutical therapies for BPD.

Surfaxin was shown to be generally safe and well-tolerated. Top-line results demonstrated that infants treated with up to five incremental standard doses of Surfaxin experienced:

* a lower incidence of death or BPD,

* a higher survival rate thr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:5/15/2008)...wswire/ -- Tigris Pharmaceuticals,Inc. announced ...Development Agreement (CRADA) with the National Ca...d preclinical development of AFP-464, an,aminoflav...onverted to,metabolites which bind covalently to D...his is part of a four-year CRADA encompassing mult...
(Date:5/15/2008)...n Antiplatelet Therapy that, Combined, with Aspiri...avix/Iscover and Aspirin, According to a New R...y 15 /- Decision Resources, one of th...pharmaceutical and,healthcare issues, finds that D...nt in patient compared to Sanofi-Aventis/Bristol M...
(Date:5/15/2008)...A Trial data reports in third quarter ...RNewswire-FirstCall/ -- VIA Pharmaceuticals,Inc. ...on the development of,compounds for the treatment ... has completed patient enrollment in its acute cor...f three Phase 2 trials investigating VIA-2291,the...
(Date:5/15/2008)... Meeting of The American Society of Ped...INE, Calif., May 15 /- IDM ...announced the presentation of updated data,from a ...e (L-MTP-PE) in,patients with lung metastases as a... and often fatal bone tumor that typically affects...
Breaking Medicine Technology:Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6The Gender Divide Starts Over Dinner 14720 1The Gender Divide Starts Over Dinner 14720 2The Gender Divide Starts Over Dinner 14720 3American Transplant Congress 2008 Critical New Data to be Revealed in Toronto 14718 1American Transplant Congress 2008 Critical New Data to be Revealed in Toronto 14718 2Reducing carbon emissions could help not harm US economy 14715 1Reducing carbon emissions could help not harm US economy 14715 2eMPR Digital Drug Reference Reaches 50 000 Downloads and the Publisher Launches a Raffle for Healthcare Providers 14711 1eMPR Digital Drug Reference Reaches 50 000 Downloads and the Publisher Launches a Raffle for Healthcare Providers 14711 2eMPR Digital Drug Reference Reaches 50 000 Downloads and the Publisher Launches a Raffle for Healthcare Providers 14711 3
...INESS WIRE)--May 4, 2007 - Argos Therapeutics,toda...suppressive,properties of soluble CD83 at the 7th ...n Francisco, May 5-9. The presentations,will be ma...ity of,Western Ontario., "These data suggest that ...ransplantation, and that it can also act,synergist...
...WIRE)--May 3, 2007 - New data show the,investigati...orea,associated with Huntington,s disease (HD) up ...pleted treatment in a 13-week trial.,These data su...to,sustain reduced chorea burden in long-term use....t of,tetrabenazine as maintenance therapy for U.S....
Other Medicine Technology:Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3
(Date:5/16/2008)...ne who would benefit most from chemo after surgery...ay News) -- A panel of 15 genes may help determine...ng cancer will experience a recurrence and, theref...dy shows. , By extension, the same genetic sig...sive forms of the cancer who would be able to fore...
(Date:5/16/2008)... Focus on Millions of Children Still in Danger, N...UNICEF and The,Advertising Council today announced...of national public service announcements (PSAs) fi... Nicole Ritchie, Joel Madden, David,Duchovny, Tea ...rs of the,Myanmar cyclone. The Ad Council is distr...
(Date:5/16/2008)...ts:, - 2007 Comprehensive Income increased 42% to...5.9 million, - 2007 Gross Margin of 76%, - Produ...0% to $12.2 million from $2.4 million as of Dec...RNewswire-FirstCall/ -- Huiheng,Medical, Inc. ("Hu...), a,China-based leader in the development, sales ...
(Date:5/16/2008)... /PRNewswire-USNewswire/ -- The Centers for Diseas...Toxic Substances and,Disease Registry (ATSDR) have...provement Award for 2008. Since its 1999 inception... (DSNS) in the CDC Coordinating Office,for Terrori... Health,Systems Management group, supplemented by ...
Breaking Medicine News(10 mins):Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 2Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 3Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 4Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 5Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 6
...o researchers, a new technique for detecting ovari...otential. Researchers in the US are using cutting-...te healthy from diseased tissue. Proteomics involv... detecting and analysing the different protein mol...
...ays heart failure victims who get a new kind of pa...pitalized with worsening heart trouble.// The devi...ed in more than 3,000 people in the US since its a...or people with a particular form of heart failure,...
...usands of bypass patients suffer mental decline af...and remembering. One leading theory is that the he...a new study,// the loss of mental sharpness suffer...fter surgery may not be caused by the heart-lung m...
... form Australia have correlated a molecular 'switc... levels fall, a finding that could provide the bas...e and heart attack.// A team from the University o...artment and CSIRO Health Sciences and Nutrition re...
Other Medicine News:Health News:A new recovery for heart attacks, 2
Inquire
...alternative to using positive displacement pipetto... PCR(a), pipetting radioactive materials and genet...r tissue culture, gel loading, serological assays ...taminants and liquids from reaching the pipet barr...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human
...nals and contamination caused by aerosols. Scienti...offer performance and economy when working with am...es, tissue culture fluids, infectious samples, for...r Tips are made with an inert ultrahydrophobic HDP...
Medicine Products: